RTX A/S
17.3.2021 15:19:21 CET | Globenewswire | Press release
Nørresundby, Denmark, 17 March 2021
Announcement no. 19/2021
Today, 17 March 2021, RTX A/S held an Extraordinary General Meeting at which the following resolutions were adopted based on proposals from the Board of Directors thereby confirming such resolutions adopted at the Annual General Meeting on 28 January 2021 and thus finally adopting the resolutions:
- Amendment of the Company’s Articles of Association article 5.3 regarding the name of the external central securities depository (item 1).
- Amendment of the Company’s Articles of Association article 5.4 regarding the name of the external keeper of the Company’s register of shareholders (item 2).
- Amendment of the Company’s Articles of Association article 6.2 regarding authorization to the Board of Directors to resolve to hold partial or full electronic general meetings (item 3).
- Authorization to attorney Henrik Møgelmose to inform the Danish Business Authority of the resolutions passed and to make any resulting changes to the Company’s Articles of Associations (item 4).
Yours sincerely
PETER THOSTRUP PETER RØPKE
Chairman President & CEO
Questions and further information
CEO Peter Røpke, tel: +45 96 32 23 00
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Fast Ejendom Danmark29.3.2026 18:17:55 CEST | Pressemeddelelse
Aktietilbagekøbsprogram
Newcap Holdings29.3.2026 12:19:20 CEST | Pressemeddelelse
NewCap Holding A/S har indgået en aftale, betinget af underskrivelse af endelige aftaledokumenter m.v., om erhvervelse af dansk selskab indenfor compliance og risikostyringsservices – Intern viden
Novartis Pharma AG29.3.2026 07:15:00 CEST | Press release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
MoonLake Immunotherapeutics AG28.3.2026 20:00:00 CET | Press release
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
